Local thrombolytic therapy in cancer patients with central venous catheter occlusion in urgent need of antiblastic treatment: A single institution experience

Journal of Thrombosis and Thrombolysis

Volumn 15, Issue 2, 2003, Pages 109-111

  Agazzi, Alberto ^a   Laszlo, Daniele ^a   Orsi, Franco ^a   Biffi, Roberto ^a   Martinelli, Giovanni ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMSACRINE; ANTINEOPLASTIC AGENT; CARMUSTINE; COUMARIN; CYTARABINE; ETOPOSIDE; FIBRINOLYTIC AGENT; LOW MOLECULAR WEIGHT HEPARIN; MELPHALAN; UROKINASE;

ADULT; AGED; ARTICLE; BLOOD CLOT LYSIS; CANCER; CANCER CHEMOTHERAPY; CANCER STAGING; CASE REPORT; CENTRAL VENOUS CATHETERIZATION; DEEP VEIN THROMBOSIS; DOSE RESPONSE; DRUG MEGADOSE; FEVER; HODGKIN DISEASE; HUMAN; MANTLE CELL LYMPHOMA; NONHODGKIN LYMPHOMA; PARTIAL THROMBOPLASTIN TIME; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; PROTHROMBIN TIME; RELAPSE; SEPSIS; STEM CELL TRANSPLANTATION; THROMBOCYTE COUNT; VEIN OCCLUSION;

ADULT; AGED; CATHETERIZATION, CENTRAL VENOUS; HEMATOLOGIC NEOPLASMS; HUMANS; MIDDLE AGED; PHLEBOGRAPHY; THROMBOLYTIC THERAPY; THROMBOSIS; TREATMENT OUTCOME;

EID: 0344740744     PISSN: 09295305     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:THRO.0000003324.54575.1f     Document Type: Article

References (14)

1. Monreal M, Ester D, et al. Thrombotic complications of Central Venous Catheters in cancer patients. Acta Haematologica 2001;106:69-72.
2. Radd II, Luna M, Kahil SAM, Costerton JW, Lam C, Bodey GP. The relationship between the thrombotic and infection complications of central catheters. JAMA 1994;271:1014-1016.
3. Monreal M, Lafoz E, Ruiz J, Valls R, Alastrue A, Upper-extremity deep vein thrombosis and pulmonary embolism. A prospective study. Chest 1991;9:280-283.
4. Lyon RD, Griggs KA, Johnson AM, Olsen JR. Long-term follow-up of upper extremity implanted venous access devices in oncology patients. J Vasc Interv Radiol 1999;10:463-471.
5. Joffe HV, Goldhaber SZ. Upper-extremity deep vein thrombosis. Circulation 2002;106(14):1874-1880.
6. Monreal M, Alastrue A, Rull M, et al. Upper extremity deep venous thrombosis in cancer patients with venous access devices. Prophilaxis with low molecular weight heparin (Fragmin). Thromb Haemost 1994;75:251-253.
7. Bern MM, Lokich JJ, Wallach SR, et al. Very low doses of Warfarin can prevent thrombosis in central venous catheters. A randomised prospective trial. Ann Intern Med 1990;112-423.
8. Bona RD. Thrombotic complications of central venous catheters in cancer patients. Semin Thromb Haemost 1999;25:147-155.
9. Lersch C, Eckel F, Sader R, et al. Initial experience with Healthport miniMax and other peripheral arm ports in patients with advanced gastrointestinal malignancies. Oncology 1999;57:269-275.
10. Cunningham MJ, Collins MB, Kredentser DC, Malfetano JH. Peripheral infusion ports for central venous access in patients with gynecological malignancies. Gynecol Oncol 1996;60:397-399.
11. Bern MM, Lokich JJ, Wallach SR, et al. Very low doses of warfarin can prevent thrombosis in central venous catheters. A randomized prospective trial. Ann Intern Med 1990;112:423-428.
12. Monreal M, Alastrue A, Rull M, et al. Upper extremity deep venous thrombosis in cancer patients with venous access devices: Prophylaxis with a low molecular weight heparin (fragmin). Thromb Haemost 1996;75:251-253.
13. Mismetti P, Mille D, La Porte S, et al. Low-molecular-weight heparin (nadroparin) and very low doses of warfarin in the prevention of upper extremity thrombosis in cancer patients with indwelling long-term central venous catheters: A pilot randomized trial. Haematologica 2003;88:67-73.
14. Lagro SW, Verdonck LF, Borel Rinkes IH, Dekker AW. No effect of nadroparin prophylaxis in the prevention of central venous catheter (CVC)-associated thrombosis in bone marrow transplant recipients. Bone Marrow Transplantation 2000;26(10):1203-1210.